FDA adds neurosurgical patties to shortage list as supply issues continue
The FDA has added neurosurgical patties to its medical device shortage list, a sign that some hospitals may need to conserve supplies and plan around limited availability. At the same time, the agency posted a nationwide recall of one Sun Pharma doxorubicin product lot because of possible glass particles in some vials.
The FDA has added neurosurgical patties to its medical device shortage list, signaling another supply problem that hospitals and surgical teams may need to manage carefully. Separately, the agency posted a nationwide recall of one lot of doxorubicin hydrochloride liposome injection after the manufacturer reported possible glass particles in some vials.
For patients, the main message is not to panic, but to pay attention if you are scheduled for surgery or receive cancer treatment with a recalled medication. If you are worried about access to a prescribed drug or device, a pharmacist, surgeon, oncologist, or hospital care team can help explain whether the issue is local, temporary, or part of a broader shortage.
What the FDA added to the shortage list
On May 6, 2026, the FDA updated its medical device shortages list to add neurosurgical patties, which are used in some brain and nerve surgeries. The agency said the shortage reflects an interruption in supply and estimated availability through the fourth quarter of 2026. The FDA also said it had issued a letter to health care providers about conservation and prioritization strategies.
The FDA notes that a device appearing on the shortage list does not always mean patient care has already been affected. In practice, the listing is meant to improve transparency and help hospitals plan.
Why drug shortages and device shortages matter differently
The FDA defines a drug shortage as a situation in which demand or projected demand in the United States exceeds supply nationwide. The agency also says many stockouts are local or temporary, even when they are not true nationwide shortages. That distinction matters because a pharmacy running low on a medication does not always mean the drug is unavailable everywhere.
For some shortages, the FDA may allow limited compounding under specific rules. But compounding is not a simple substitute for an approved product, and the limits change when a shortage is resolved.
What the doxorubicin recall means
On May 13, 2026, the FDA posted Sun Pharmaceutical Industries’ voluntary U.S. recall of one lot of doxorubicin hydrochloride liposome injection, 50 mg/25 mL, due to possible glass particles. The recall covered lot HAG2581B and was described as a hospital/user-level recall.
According to the FDA-posted announcement, glass particles given intravenously may cause local irritation or swelling, and more serious risks could include blockage of blood vessels or life-threatening blood clots. Sun Pharma said it had not received reports of adverse events tied to the recalled batch at the time of the notice.
The product is used for certain cancers, including ovarian cancer, AIDS-related Kaposi sarcoma, and multiple myeloma. The FDA said hospitals, distributors, retailers, and users with the product should stop using it and return or discard it as directed.
Who may be affected
People most likely to notice these developments are patients with planned surgery, especially neurosurgery, and patients receiving specialty cancer care. Caregivers may also need to help track whether a medication or device on a treatment plan is included in a recall or shortage.
Hospitals and outpatient centers may need to adjust purchasing, scheduling, and conservation plans if supplies are limited. For patients, that can translate into delays, substitutions, or extra calls from a care team.
What readers can do
If you are expecting surgery or infusion treatment, ask your care team whether the device or drug being used is affected by a shortage or recall. If you already received the recalled doxorubicin product and have symptoms you think could be related, contact your clinician promptly. Seek urgent care right away for severe symptoms such as chest pain, trouble breathing, fainting, or signs of a blood clot.
If you are having trouble filling a prescription, ask your pharmacist whether the issue is a local stock problem or a national shortage listed by the FDA. That can help determine whether another pharmacy, a different formulation, or a clinician-reviewed alternative may be available.
The larger picture is that supply disruptions can affect both medicines and medical devices, even when the problem is not immediately visible to patients. FDA shortage tracking is meant to give providers and families earlier warning, but it does not eliminate the underlying access problem.
Sources
- FDA Medical Device Shortages List
- FDA Drug Shortages
- FDA Frequently Asked Questions about Drug Shortages
- FDA Recalls, Market Withdrawals, & Safety Alerts
- CDC Medication Safety and Your Health
- FDA Compounding when Drugs are on FDA’s Drug Shortages List
Editorial note: Weence articles are researched from cited public-health, medical, regulatory, journal, and reputable news sources and may be drafted with AI assistance. They are checked for source support, clarity, and safety guardrails before publication.
This article is for general informational purposes only and is not medical advice. Research findings can be early or incomplete, and health guidance can change. Always talk with a qualified healthcare professional about personal symptoms, diagnosis, medications, vaccines, screenings, or treatment decisions. If you think you may have a medical emergency, call emergency services right away.
